The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of toxicity, efficacy, and dose modifications in obese and non-obese patients receiving modified FOLFOX6 (mFOLFOX) for metastatic colorectal cancer (mCRC).
Daniel Jerzy Wojenski
No relevant relationships to disclose
Heidi D. Finnes
No relevant relationships to disclose
Ross A. Dierkhising
No relevant relationships to disclose
Kristen Beth McCullough
No relevant relationships to disclose
Steven R. Alberts
No relevant relationships to disclose